Paul Audhya Sells 2,685 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,685 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $71,904.30. Following the transaction, the insider owned 147,499 shares of the company’s stock, valued at approximately $3,950,023.22. The trade was a 1.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Down 0.1%

KalVista Pharmaceuticals stock opened at $26.79 on Thursday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $26.85. The firm has a 50 day moving average price of $21.94 and a two-hundred day moving average price of $17.65. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. Equities analysts predict that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently modified their holdings of KALV. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $24,360,000. Vestal Point Capital LP grew its position in KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares during the period. Parkman Healthcare Partners LLC grew its position in KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the period. Ameriprise Financial Inc. grew its position in KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after purchasing an additional 905,053 shares during the period. Finally, Elmind Capital LP acquired a new stake in KalVista Pharmaceuticals in the 4th quarter valued at $12,941,000.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on KALV shares. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. HC Wainwright downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $37.00 to $27.00 in a research report on Friday, May 1st. Citizens Jmp downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.